At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
Tbo-filgrastim +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Trial Evaluating the Use of G-CSF After Plerixafor-Mobilized Autologous Stem Cell Transplant (Auto HSCT)
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted Oct 23, 2017·Updated Dec 17, 2025
In Brief
A Phase 2 clinical trial evaluating Hematopoietic Cell Transplantation, Tbo-filgrastim, and 1 other intervention for Non-Hodgkin's Lymphoma and Plasma Cell Myeloma. Completed, enrolled 77 participants across 1 site.
Detailed Summary
This phase II trial studies how well stem cell transplant with or without tbo-filgrastim works in treating patients with multiple myeloma or non-Hodgkin lymphoma. Eliminating the use of tbo-filgrastim after transplant may still help maintain a similar time to discharge.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma, Plasma Cell Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedOct 2017
Primary CompletionJun 2021
Study CompletionNov 2022
TodayJul 2026
First PostedOct 23, 2017
Enrollment StartOct 12, 2017
Primary CompletionJun 1, 2021
Study CompletionNov 16, 2022
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.7 years ago
Interventions
Hematopoietic Cell Transplantationprocedure
Undergo auto HSCT
Tbo-filgrastimdrug
Given subcutaneously
Laboratory Biomarker Analysisother
Correlative Studies